Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/39053| Title: | Efficacy and persistence between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation | Authors: | Zhu, C. Kalincik, T. Horakova, D. Zhen, Z. Buzzard, K. Skibina, O. Alroughani, R. Izquierdo, G. Eichau, S. Kuhle, J. Patti, F. Grand'Maison, F. Hodgkinson, S. Grammond, P. Lechner-Scott, J. Butler, E. Prat, A. Girard, M. Duquette, P. Macdonell, R. Weinstock-Guttman, B. Ozakbas, S. Slee, M. Sa, M. Jose Van Pesch, V. Barnett, M. VAN WIJMEERSCH, Bart Gerlach, O. Prevost, J. Terzi, M. Boz, C. Laureys, G. Van Hijfte, L. Kermode, A. Garber, J. Yamout, B. Khoury, S. J. Jokubaitis, V. Monif, M. Merlo, D. Van der Walt, A. Butzkueven, H. |
Issue Date: | 2022 | Publisher: | SAGE PUBLICATIONS LTD | Source: | Multiple Sclerosis Journal, 28 (S3) , p. 645 -647 | Document URI: | http://hdl.handle.net/1942/39053 | ISSN: | 1352-4585 | e-ISSN: | 1477-0970 | ISI #: | 000866540802331 | Category: | M | Type: | Journal Contribution |
| Appears in Collections: | Research publications |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Efficacy and persistence between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation.pdf | Published version | 7.12 MB | Adobe PDF | View/Open |
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.